Hepatitis Inequalities Study

Overcoming Inequalities in Health to Eliminate Hepatitis - Real-World Evidence from a Territory-Wide Cohort

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06596213

Enrollment

100000

Registered

2024-09-19

Start date

2024-10-01

Completion date

2031-06-30

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B, HEPATITIS C VIRUS CHRONIC INFECTION

Brief summary

Health inequality in liver diseases including age, gender, ethnicity and socioeconomic status has been increasingly recognised and potentially hinder hepatitis elimination. Health inequality has significant impact to evaluate the impact diagnostic and treatment uptake rates of chronic viral hepatitis on risk of hepatocellular carcinoma (HCC), hepatic event and liver-related death in patients with chronic hepatitis B and/or C. To overcome the limitation of small prospective cohort study of limited recruitment period, retrieving information from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority (HA) will be one of the best way to answer these questions.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients will be eligible if they have any of these viral markers (HBeAg / HBsAg / HBV DNA / HCV RNA) and/or any of the following diagnosis codes (ICD-9 070-070.9; 348.3, 349.82, 456, 456.2, 456.8, 567.2, 567.8, 570, 571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 789.5) checked or coded in any public hospitals or clinics from 1 January 2000 to 31 March 2024.

Exclusion criteria

* Patients with missing age, gender, ethnicity and socioeconomic status * (Subgroup analysis for ethnicity and socioeconomic status) Patients with missing ethnicity and socioeconomic status * Serious medical illnesses or malignancy with life expectancy <1 year

Design outcomes

Primary

Measure	Time frame	Description
Safety	From 1 January 2000 to 31 March 2024	Time from diagnosis of hepatitis to treatment.

Secondary

Measure	Time frame	Description
Safety	From 1 January 2000 to 31 March 2024	The composite endpoints of recurrence of hepatic events (e.g. HCC hepatic coma, portal hypertension, variceal bleeding, hepatorenal syndrome).

Contacts

Primary ContactAngel Chim, MSc

angelchim@cuhk.edu.hk852-35053759

Backup ContactGrace Wong, MD

wonglaihung@cuhk.edu.hk852-35054205

Outcome results